# ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 YTD Q3 P&L / Income Statement

- Company: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Period: 2025-10-01 to 2026-06-30
- Filing: Q3 FY2026 10-Q, filed 2026-08-04, accession number 0000879407-26-000057
- Page: https://plicit.ai/financials/arwr/fy2026-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/arwr-fy2026-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Counterparty Name

Income statement for 2025-10-01 through 2026-06-30. View: Counterparty Name. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 413,023,000 US dollars
- **Total operating expenses**: 683,567,000 US dollars
- **Operating (loss) income**: negative 270,544,000 US dollars
- **Total other (expense) income**: negative 17,659,000 US dollars
- **(Loss) income before income tax expense (benefit) and noncontrolling interest**: negative 288,203,000 US dollars
- **Income tax expense (benefit)**: 46,000 US dollars
- **Net (loss) income including noncontrolling interest**: negative 288,249,000 US dollars
- **Glaxosmithkline Intellectual Property Limited**: 0 US dollars
- **Madrigal**: 25,000,000 US dollars
- **Novartis**: 74,945,000 US dollars
- **Sanofi**: 11,983,000 US dollars
- **Sarepta**: 297,594,000 US dollars
- **Undisclosed (calculated)**: 3,501,000 US dollars
- **Total operating expenses**: 683,567,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to ARROWHEAD PHARMACEUTICALS, INC.: −$296.21 M; to noncontrolling interests: $7.96 M.